CorMedix announces commercial agreement with dialysis provider

CorMedix has entered into a multi-year commercial supply contract with a top tier midsized dialysis provider for the supply of DefenCath. CorMedix received NDA approval of DefenCath under the Limited Population Pathway for Antibacterial and Antifungal Drugs on November 15, 2023, and began commercialization of the product in the inpatient setting on April 15th. The Company expects to begin commercialization in outpatient dialysis clinics in July. This agreement will allow for patients to have access to DefenCath at more than 500 dialysis facilities located nationally.